Navigation Links
Eaton Scientific Expands Investor Relations Strategy and Launches Important New Website Content
Date:9/19/2012

BEVERLY HILLS, Calif., Sept. 19, 2012 /PRNewswire/ -- Eaton Scientific Systems, Ltd. ("Eaton" or the "Company") a wholly-owned subsidiary of Pristine Solutions, Inc. (OTCQB: PRTN) is pleased to announce that it has engaged Capital Group Communications, Inc. ("CGC") to assists the Company in an expanded investor relations strategy. CGC will assume the day-to-day investor relations functions and undertake a comprehensive program to introduce new potential investors to the Company.

"The addition of Capital Group to the Pristine and Eaton Scientific teams will assist us in supporting an expanded investor relations and communications effort within the investment community and the mainstream media," stated Michael Borkowski, CEO of Eaton Scientific.  "We look forward to working with CGC to grow, service, and maintain our valuable shareholder base and to expose a larger audience to our compelling products and corporate growth potential."

San Francisco-based CGC is a leading consulting firm specializing in the creation and implementation of comprehensive investor, public and media relations for venture stage and emerging growth companies. CGC utilizes a long-term, collaborative business model whose strength has always been its relationships.

In addition, the Company has also recently launched several important new content features to its corporate website at www.eatonscientific.com.  New features include detailed scientific information concerning Tropine 3 (Homatropine) and many new links/content/video related to the recent support and endorsement from leading women's sexual health expert, Dr. Jennifer R. Berman, MD.  All shareholders and other interested parties are encouraged to visit the website to review the new material.

About Pristine Solutions, Inc.

Pristine Solutions, Inc., through its wholly-owned subsidiary company, Eaton Scientific Systems, Ltd., holds the intellectual property and global marketing rights to Tropine 3, a patent pending novel indication of an existing FDA approved drug for the non- hormonal treatment of hot flashes in pre-menopausal, peri- menopausal, and post-menopausal women. The company is preparing for Phase 1 & 2 Clinical Trials with the goal of FDA approval of Tropine 3.

Forward-Looking Statements/Disclaimer

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pristine Solutions' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Pristine Solutions' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Pristine Solutions herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Pristine Solutions disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.


'/>"/>
SOURCE Eaton Scientific Systems, Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Eaton Scientific Teams Up with Renowned Womens Sexual Health Expert Dr. Jennifer R. Berman, MD and Berman Sexual Health to Advance Tropine 3 Trials and Marketing
2. Eaton Scientific Systems, Ltd. completes its Study Protocol for its Planned Clinical Trial of its Patent Pending Non-Hormonal Treatment of Hot Flashes.
3. Eaton Scientific Enters Agreement with RoxSan Pharmacy to Provide Tropine 3 for its upcoming Clinical Trial Participants
4. Eaton Scientific Discusses Positive Anecdotal Feedback from Pharmacist Compounding Homatropine for Doctors Treating Patients Experiencing Hot Flash Symptoms in the Beverley Hills and Los Angeles Area.
5. Eaton Scientific Announces Clinical Trial Plans for Tropine 3 - Company to Seek FDA Approval as Novel Prescription Drug for Non-Hormonal Treatment of Hot Flashes in Menopausal Women
6. Eaton Scientific Systems Confirms Acquisition and Status of Tropine 3 Patent Pending Non-Hormonal Treatment of Hot Flashes in Menopausal Women
7. Pristine Solutions, Inc. Completes Acquisition of Eaton Scientific Systems, Ltd. - Enters Multi-Billion Dollar Womens Health and Drug Sector
8. Clinilabs Opens Phase I Unit In Eatontown, New Jersey
9. Boston Scientific to Acquire BridgePoint Medical, Inc.
10. Boston Scientific to Participate in the 2012 Morgan Stanley Global Healthcare Conference
11. Islet Sciences Appoints Dr. Kevan Herold and Dr. Morton Printz to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... -- Australia Glaucoma Surgery Devices Market Outlook to ... Glaucoma Surgery Devices Market Outlook to 2022", provides ... Devices market. The report provides value, in millions ... prices (USD) within market segement - Glaucoma Drainage ... and distribution shares data for each of these ...
(Date:12/8/2016)... 2016 KEY FINDINGS The global ... 2017-2023. Various reasons for growth of the medical lifting ... of chronic diseases, high recovery cost of injuries and ... Medical lifting sling refers to an assistive device that ... slings connect to the lift and hold the patient. ...
(Date:12/8/2016)... Lilly and Company (NYSE: LLY ) today ... at the 9 th Clinical Trials on Alzheimer,s ... meet the primary endpoint in the EXPEDITION3 clinical trial, ... dementia due to Alzheimer,s disease (AD), and Lilly will ... of mild dementia due to AD. ...
Breaking Medicine Technology:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... miniature, folded, pharmaceutical inserts and outserts. As a means of expanding capabilities ... addition will enable Flottman to individually code professional inserts (PIs) and patient package ...
(Date:12/9/2016)... NY (PRWEB) , ... December 09, 2016 , ... ... and Drug Dependence, Inc. (NCADD) is recommending the film Whispering Spirits ... and the District of Columbia as an education tool in the war against teen ...
(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, Va., wanted ... all types of amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves ... use and could be set up in a matter of minutes, or even seconds. ...
(Date:12/9/2016)... ... 09, 2016 , ... The Holy Name Medical Center Foundation ... on December 3rd, to benefit Holy Name Medical Center's programs and services. More ... over $1 million - the largest event in the Center's history, both in ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying to get ... thought that if the nebulizer had a more child-friendly design, then children would be ... developed the patent-pending NEBY to avoid the need to deliver medication via a nebulizer ...
Breaking Medicine News(10 mins):